Shi et al., showed that in a mouse model of HCC, the use of sorafenib and stimulation of DCs with exosomes from tumor cells reduced the number of regulatory T cells and increased the count of CD8+ T cells [103]. This evidence concerns the gene CD8A and neoplasm.